Impax Asset Management Group plc Has $7.80 Million Stock Holdings in GeneDx Holdings Corp. $WGS

Impax Asset Management Group plc raised its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 20.0% during the 4th quarter, HoldingsChannel reports. The firm owned 60,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. Impax Asset Management Group plc’s holdings in GeneDx were worth $7,804,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in WGS. Royal Bank of Canada grew its holdings in GeneDx by 30.2% during the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in GeneDx by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after purchasing an additional 453 shares during the last quarter. NewEdge Advisors LLC grew its holdings in GeneDx by 270,700.0% during the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in GeneDx by 67.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after buying an additional 11,375 shares during the period. Finally, Cetera Investment Advisers bought a new position in GeneDx in the 2nd quarter worth approximately $249,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insider Buying and Selling at GeneDx

In other GeneDx news, COO Bryan Dechairo sold 5,961 shares of GeneDx stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total transaction of $510,857.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Katherine Stueland sold 46,933 shares of the business’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $63.17, for a total transaction of $2,964,757.61. Following the completion of the sale, the chief executive officer directly owned 91,514 shares in the company, valued at $5,780,939.38. This trade represents a 33.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 112,808 shares of company stock worth $8,245,748 over the last three months. 29.60% of the stock is currently owned by corporate insiders.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $68.53 on Friday. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. The business’s 50 day moving average is $73.57 and its two-hundred day moving average is $108.91. The company has a market cap of $2.01 billion, a P/E ratio of -91.37 and a beta of 2.17. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. The company had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. On average, equities analysts expect that GeneDx Holdings Corp. will post 0.75 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on WGS. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Jefferies Financial Group set a $150.00 price target on GeneDx in a research report on Monday, February 23rd. Canaccord Genuity Group set a $100.00 price target on GeneDx and gave the stock a “buy” rating in a research report on Monday, April 20th. Finally, Wells Fargo & Company raised GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price target on the stock in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and an average price target of $130.71.

Get Our Latest Stock Report on GeneDx

GeneDx Profile

(Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

Featured Articles

• Five stocks we like better than GeneDx

Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).